aTYR PHARMA (ATYR) EBITDA (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly EBITDA came in at -$11.4 million in Q1 2026, up 27.5% YoY from -$9.0 million in Q1 2025, and up 22.71% on a QoQ basis from -$14.8 million in Q4 2025.
aTYR PHARMA (ATYR) EBITDA (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of EBITDA data on file, last reported at -$11.4 million in Q1 2026.
- Quarterly EBITDA rose 27.5% year-over-year to -$11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73.3 million (down 9.3% YoY) and the FY2025 annual result came in at -$77.6 million, down 14.3% from the prior year.
- EBITDA grew to -$11.4 million in Q1 2026, from -$14.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$8.0 million in Q4 2022 to a low of -$26.7 million in Q3 2025.
- A 5-year average of -$15.2 million and a median of -$14.8 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA plunged 100.74% — and 2026, when it grew 27.5%.
- Tracing ATYR's EBITDA over 5 years: stood at -$8.0 million in 2022, then sank by 100.74% to -$16.0 million in 2023, then grew by 0.87% to -$15.8 million in 2024, then grew by 6.47% to -$14.8 million in 2025, then advanced by 22.71% to -$11.4 million in 2026.
- The last three EBITDA figures came in at -$11.4 million (Q1 2026), -$14.8 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | aTYR PHARMA | 49.34 Mn | -8.08 Mn | - | -10.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.88 Mn |
| Mar 31, 2026 | -11.44 Mn |
| Dec 31, 2025 | -14.80 Mn |
| Sep 30, 2025 | -26.75 Mn |
| Jun 30, 2025 | -20.31 Mn |
| Mar 31, 2025 | -15.77 Mn |
| Dec 31, 2024 | -15.82 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Jun 30, 2024 | -17.32 Mn |
| Mar 31, 2024 | -16.64 Mn |
| Dec 31, 2023 | -15.96 Mn |
| Sep 30, 2023 | -12.62 Mn |
| Jun 30, 2023 | -13.56 Mn |
| Mar 31, 2023 | -12.79 Mn |
| Dec 31, 2022 | -7.95 Mn |
| Sep 30, 2022 | -13.49 Mn |
| Jun 30, 2022 | -12.58 Mn |
| Mar 31, 2022 | -12.38 Mn |
| Dec 31, 2021 | -8.64 Mn |
| Sep 30, 2021 | -7.73 Mn |